(VEGF), which then can regulate angiogenesis (Bergers 1982) . In wild-type mice, BM hematopoietic and stromal cells expressed MMP-9 three days after treatment with et al., 2000) or osteoclast recruitment (Engsig et al., 2000) . Accordingly, we asked whether MMPs contribute 5-FU ( Figure 1C ). These data suggest that both pro-MMP-9 and MMP-9 are upregulated in BM cells after to the release of stem cell-active cytokines following stress that shifts stem cells and progenitors from a quimyelosuppression. escent to a proliferative niche essential to reconstitute the stem cell pool and hematopoietic recovery.
MMP-9 Ϫ/Ϫ Mice Show Delayed Hematopoietic Recovery Following 5-FU Treatment
To understand the role of MMP-9 in promoting HSC Results recruitment and hematopoietic recovery after BM suppression, we used MMP-9-deficient mice. Under steady-BM Suppression Induces MMP-9 Expression in BM Cells state conditions, adult MMP-9 Ϫ/Ϫ and MMP-9 ϩ/ϩ mice have similar peripheral white blood cell (WBC) counts While BM suppression with 5-FU results in apoptosis of actively cycling HSCs and progenitor cells, it does not and both became leukopenic within six days after 5-FU treatment ( Figure 2A ). However, in 5-FU-treated MMPaffect HSCs in G0 of cell cycle. This model is ideal for studying factors that promote recruitment of HSCs dur-9 Ϫ/Ϫ mice, the recovery of WBC ( Figure 2A ) and platelets (data not shown) was delayed by an additional 8 days. ing hematopoietic reconstitution. We found an increase in pro-MMP-9 ( Figure 1A ) and active MMP-9 ( Figure 1B ϩ/ϩ and MMP-9 Ϫ/Ϫ mice. However, followand progenitor cells into the vascular zone and the lack of differentiation into myeloid and megakaryocytic lining 5-FU myeloablation, the number of these cells entering S phase of cell cycle was impaired in MMP-9 Ϫ/Ϫ eages in MMP-9 Ϫ/Ϫ mice led us to hypothesize that MMP-9 may exert its effects through the release of a mice. These data suggest that although during steadystate hematopoiesis there is no difference in the number stem cell-active cytokine. of cycling repopulating cells, in the recovery phase after myelosuppression, lack of MMP-9 results in a diminished recruitment of cycling cells leading to profound suppression process is the release of sKitL, then imTo determine whether chemo/cytokines induce paired hematopoietic cell mobilization following SDF-1 MMP-9 expression in vivo, we introduced SDF-1, VEGF, and VEGF treatment of MMP-9 Ϫ/Ϫ mice could be due to and G-CSF into wild-type mice. BM of the mice treated their inability to produce sKitL. Indeed, we observed with SDF-1, VEGF, or G-CSF showed increased immuincreased plasma sKitL levels in MMP-9 ϩ/ϩ mice after noreactive MMP-9 on stromal and hematopoietic cells treatment with SDF-1, VEGF, and G-CSF as compared (Figures 5Bc, d , e, and f). These studies raised the possito untreated animals ( Figure 6F ). This chemo/cytokinebility that chemo/cytokine-induced MMP-9 activation induced upregulation of sKitL was impaired in MMP-9 units (CFU-EC) and the expression of VEGF-receptor-2 strate a key role for MMP-9 to rapidly release the stem cell-active cytokine sKitL, thereby directing stem and (VEGFR2; Figures 7A and 7B) . In contrast, VEGF did not progenitor cell recruitment and facilitating hematopoimobilize CFU-EC or VEGFR2 ϩ cells into the circulation etic reconstitution. This is schematically represented in of wild-type mice treated with MPI ( Figures 7A and 7B) . cell niche for c-Kit negative stem and progenitor cells.
CFU-S Assay
Mobilized PBMCs (10 5 /mouse) of chemokine-treated SCID mice Experimental Procedures were injected i.v. into lethally irradiated syngeneic recipients (9 Gy). Spleens were removed 12 days later and fixed in Bouin's solution.
Animal Studies
The number of macroscopic spleen colonies was scored. SCID mice, age and sex-matched (7-8 weeks), weight (Ͼ20 g) were BM Repopulating Assay purchased from the Jackson Laboratory (Bar Harbor, ME).
Chemo/cytokine-mobilized PBMCs from SCID mice treated with/ MMP-9 Ϫ/Ϫ 129Sv mice were generated (Vu et al., 1998) and used without MPI were collected on day 7. PBMCs from G-CSF-treated after at least eight back crosses to CD1 mice. MMP-9 ϩ/ϩ 129Sv MMP-9 Ϫ/Ϫ and MMP-9 ϩ/ϩ mice were collected on day 5. Mobilized mice were obtained by back crossing MMP-9 ϩ/Ϫ 129Sv mice with PBMCs (10 5 ) were injected into lethally irradiated syngeneic animals CD1 mice. Mice were maintained in filtered germ-free air Thorensten (9.5 Gy). Survival was monitored. units. 
Endothelial Progenitor Assay

